Docusign Envelope10'. 72C94868-6C3F4A1M6EB-889E5E8F82CA Company Regislered Number: 02685083 Charlty Registered Number (England & Wales): 1009671 NATIONAL ECZEMA SOCIETY (A Company Limited by Guarantee) UNAUDITED TRUSTEES. REPORT AND FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2024 AE8Z4V4P 2710912025 COMPANIES HOUSE A22
Docusign Envelope ID.. 72C9486MC3F4A1&A6E8-889E5E8F82CA NATIONAL ECZEMA SOCIETY (A Company Llmited by Guarante8) CONTENTS Page Reference and Admlnistratlve Detalls of the Charlty, Its Trustoes and Advls•rs Trustees. Report 2-11 Trustees. Responsibilities Statement 12 Independ•nt Examlner'8 Report 13-14 Consolidaled Slaternent of Flnanclal A¢tlvltle• 15 Consolidated Balance Sheet 16-17 Charlty Balance Sheet 18-19 Consolldatod Statem•nt of Cash Flows 20 Not•s to the Flnanclal Statement8 21-45
Docusign Envetope ID.. 72C94868-6C3F4A13-A6EB-889E5E8F82CA NATIONAL ECZEMA SOCIETY (A Company Llmlted by Guarantee) REFERENCE AND ADMINISTRATIVE DETAILS OF THE CHARITY,.ITS TRUSTEES AND ADVISERS FOR THE YEAR ENDED 31 DECEMBER 2024 Trustees Stephen Pugh. Chair Hannah Kunzlik Professor Celia Moss OBE James Pitayanukul. Treasurer Hedwig Vollers Suzanne Watson Company reglstered number 02685083 Charity reglstered numb•r 1009671 R•gl$tered office 82 Tanner Street London SE13GN United Kingdom Chief executlve officer & Andrew Proctor Company secretary Independent Examiner MHA Chartered Accountants MHA House Charter Court Swansea Enterprise Park Swansea SA7 9FS Prlnclpal 8ankern CAF Bank Ltd National Westmlnster Bank plc Status and Governing Document National Eczema Society is a charitable company, limited by guarantee. It was incorporated on 6 February 1992 and registered as a charity on 10 March 1992. It is governed by its Articles of Association. Subsidiary Companies Eczema Trading Limited Page 1
(Io¢usign Envelope ID.. 72C94B684C3F4A1&A6E8-889E5E8F82CA NATIONAL ECZEMA SOCIETY (A Company Limited by Guarantee) TRUSTEES. REPORT FOR THE YEAR ENDED 31 DECEMBER 2024 The trustees present their annual report together with the financial statements of the Group and the Charity for the year 1 January 2024 to 31 December 2024. The trustees confimi thal the Annual Report and financial statements of the company comply with the current statutory requirements. the requirements of Ihe company's goveming document and the provisions of the Statement of Recommended Practice (SORP), applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland {FRS 102>. Since Ihe Charity and the Group quallfies as small under section 383, the strategic report required of medium and large companies under The Companies Act 2006 (Strategic Report and Directorfs Report) Regulations 2013 is not required. Purpose and Alms National Eczema Society was established in 1975 to support people with eczema and their families and to work on thelr behalf. The charity is celèbrating Its 50th anniversary In 2025. We remaln d8dicated to these founding principles and today we continue to help people across the UK by providing evidence-based Information and advice about eczema and Its management. We dellver thls In varlous ways through our website, webinars, instructional videos, social media communications and publi¢alions. We also provide a collective voice for people with eczema, fund and inform research, influence health policy to improve eczema care, and raise greater awareness and understanding of the condilion among people affected by eczema and the wider public. The prevalence of eczema has increased over recent decades. and around one in five children and one in ten adults are now impacted by this life-limiling Condition in the UK. While the reasons for the increase are not fully understood, il does mean the charity's work Is needed more than ever. There is no eure for eczema and. unless you have the condition, it can be hard to understand the dally challenge of living wlth relentless itching and inflamed, painful skin. Many healthcare professionals have limited dermatology tralnlng and timely access to specialist dermatology healthcare for people with eczema can often be difficult. National Eczema Society aims to provide the infomialion and support needed for people to self-manage their eczema effectively, to become experts in their own care. leam from the experiences of others, and provide the reassurance of knowing they are not on their own. Ensurlng Our Work Dellv•rs Our Charllabl• Alm8 We review our activities each year and monitor the impact of our work to ensure we continue to fulfil our purpose of supporting people affected by eczema. Among other ways, we assess the Society's P8rformance and achievements through the number of people we have helped with information and advice, the quality and consistency of the r8sources we provide. the eczema research we support. and the policy influencing we achieve. We consider how planned activities will contribute to the aims and objectives we have set, and in doing this we have referred lo the Charity Commission's general guidance on public benefit. We have had regard to the legislatlve and regulatory requirements for disclosing how our charitable objectives have provided such benefit, and complied wlth the duty sel out in section 4 of the Charities Act 2011. 2024 Activity and Achievements - Deliverlng Public Benefit All our charitable activities focus on supporting people affected by eczema and championing their needs, and further our charitable purposes for the public benefit. Here we present a summary of the Society's work over the year. Page 2
Do¢usign EnlOP0 10.. 72C94B684C3F4A1>A6EB489E5E8F82CA NATIONAL ECZEMA SOCIETY (A Company Limited by Guarantee) strategic Review and Implementation During the year we implemented a strategic review, with the purpose of enabling the charity to better serve the UK 8czema community. We are a relatively small charity. serving a very large communlty of people affected by eczema over eight million adulls and children in the UK and their families. With limited funding, il is important the charity prioritises its resources to achieve the biggest impact we can for people with eczema. Our strategy is now focusing more on our work supporting eczema research, to develop better treatments and ultimately a cure, and influencing for better eczema care for all sufferers. These enable us to become a stronger collective voice for the eczema community, as we recognise too many people are struggling to achieve a good quality of life because of their eczema and need better care. The change of focus brought about through the strategic revlew requlred some challenging cholces, Including withdrawing from providing personalised advice on managing eczema. This included taking the difficult declsion to close the Soclety's eczema helpllne seNice, In March 2024. We recognlse thls was dlsappointlng for supporters and others who have used the Society's helpline in the past and have appreclated the advice we provided. We are committed to expanding other information resources, which are used by many people in our community. We were able to 5UPPOrt around 1,000 callers a year to the helpline. The strategic review proposed a number of new staff roles, and we recruited three new members of staff during the year, to lead on the Society's health Gontenl, research engagement, and communications and campaigning work. Under the new strategy. several existing staff roles were no longer required. and it is with regret these posts were made redundant in March 2024, The Soclety's three core areas of charitable work continue to be: Provldlng eczema informatlon and advice Supporting eczema research Advocacy and improving eczema Care. Provldlng Informatlon and Advl¢e for People Llvlng wlth Eczema The Society continues to provide a wide range of high quality, evidence-based information about eczema and ils management for the UK eczema community. We produce a range of patient information booklets and factsheets about eczema management and treatment, available online and in print. We distribute printed copies at the events we organise and attend. and we provided over 17,500 copies of our printed publications to healthcare professionals during the year, for onward distribution to patients in hospital demalology clinics and other healthcare settings across the UK. Qur most popular booklets are Childhood Atopic Eczema and Itching and Scratching. National Eczema Society factsheets and booklets are updated regularfy on a rolling review cycle and checked by healthcare professionals lo ensure the information is accurate and up-to-date. We updaled and reprinted a number of publications over the year, including our Guide for Teenagers with Eczema and Eczema Guide for Healthcare Professionals. Our eczema information is available on the Society's website, which received over million visits during the year. Our webpages on facial eczema, sebofrhoeic dermalitis, emollients, eye and ear eczema, hand eczema, topical steroid treatments. topical steroid withdrawal, pompholyx eczema and scalp eczema remain especially popular. Additionally. over 35.000 copies of our factsheets were downloaded during the year. We also promote health advice messages through our social media posts, e-newsletters, media engagement and other extemal communications. In August, we launched a regular monthly email newsletter for supporters who have signed-up via our website to receive email communications from National Eczema Society. Over 10,000 people affected by Page 3
Do¢usign En¥elope10: 72C94B684C3F4A1>A6EB489E5E8F82CA NATIONAL ECZEMA SOCIETY (A Company Limlted by Guarantee) eczema now benefit from regular email updates on 8CZ8ma news and developments. and about the work of the charity. We have received positive audience feedback on our e-newsletters and the mailing list continues to grow. We launched the Exploring Eczema webinar series in September. presented by Dermatology Nurse Advisor Julie Van Onselen. We are planning eight webinars on different topics during 202412025 including. emollients, eczema triggers and managing baby and toddler eczema. Typically, beeen 100 and 200 people att8nd each of our webinars, with many more viewing the webinar recordings on our YouTube channel. We also Conlinued our popular programme of webinars with St John's DemiAcademy (part of Guy's and St Thomas, Hospital, London) to jointly deliver two events, one focusing on managing eczema itch and the other on facial eczema. Recordings of several past webinars are also available to view on the Society's social media pages or YouTube channel. As noted above, the Soclety took the decislon to close 5ts eczema helpline seNlce In March 2024, as part of a wider strategy change to focus more resources on supporting eczema research. campaigning for better eczema care, and broadening our inlormallon off&r wllh new r850urces like webinars, We contlnue to ralsg awareness of local volunteer-led patlent support groups, by provldlng Snformatlon and a presence for these groups on the Society's website. The West Surrey and North-East Hampshire Support Group held a number of fundraising events over the year and organised an information day in Guildford in February on the 'Combined Approach, to managing eczema. Dr Apa Kanji talked about how habit reversal therapy combined with topical treatments can help people with eczema break the habitual eczema itch-scratch cycle. Dr Kanji is a dermatologist worklng at St John's Institute of Dermatology in London and she leaches habit reversal therapy. The event was livestreamed and recorded on Facebook. enabling many more people with eczema to access th8 talk. NES Mombershlp Scheme National Eczema Society is a membership organisation and we are very grateful to our 2,000 members who support the Society through their annual membership fee and additional donations. Members receive our membership magazine Exchange. whlch features expert Information and news about eczema. Members are also encouraged to attend the Society's Annual General Meeting and contribule thelr ideas on the running of the charity. As in previous years. support for our charity extends far beyond our membership and we remain gratelul to all our donors. and to those members who continue to support us financially even though they no longer have any personal need of our help. Income from the membership scheme has fallen as the number of members has gradually declined over the years. We took the difficult decision to move to producing Iwo issues annually of Exchange magazine starting in 2024, replacing the previous quartedy publishing schedule. so that membership scheme costs are better aligned with membership income. Supporting Eczema Research National Eczema Society launched its first-ever eczema research call in December 2024, inviting research teams in UK universits'es to apply for funding from the charity. We want to improve the understanding and treatment of eczema and topical steroid withdrawal (TSW) and more research will help achieve this goal. Th& Society invited applications for innovation grants to fund new research ideas, as well as pump-priming grants to fund early-stage studies, enabling researchers to collect proof-of-concept data needed to take the research forward in larger studies. We also invited applications for PhD sludentships, to support the next generation of world-leading eczema researchers. The applications were assessed in Spring 2025. and the awards announced early summer 2025. It is our intention to hold an eczema research call annually. subject to sufficient charity funds being available. Pag8 4
DopJsign Envelopè ID: 72C94B68-6C3F4A13-A6EB489E5E8F82CA NATIONAL ECZEMA SOCIETY (A Company Limlted by Guarantee) Building our internal research administration capabilty. the Society applied for and joined the Association of Medical Research Charities (AMRC) and has already benefitted from the AMRC'S infomialion and policy resources and training. This UK-based group represents and supports over 150 charities that fund medical research. National Eczema Sociely has also joined the Charities Research Involvement Group {CRIG). enhancing our ability to connecl with patients, caregivers, other medical Charities and heallhcare professlonals who share our passlon for improving the Ilves of those affected by eczema. During the year we established an 'Experts by Experience, (EXEC) patlent group, to ensure the experlences and views of people living with eczema are fully considered in the Society's work. The 25-strong group includes both adults living with eczema and parents of children living with the condition. EXEC members provide feedback on eczema research initiatives. including projects funded by the Society, and a patient perspective on the Charity's wider activitles. We continue to support patient Involvement in shaping research. NES is approached regularly by researchers seeking patient views and to learn from patient experiences. It is so encouraging to see such a range of research underway and new treatments in the pipeline, following a long period when eczema was largely overlooked. The Society actively supports eczema research by participating in study steering groups, providing patient perspectives for research projects. promotin9 surveys, supporting patient recruitment for trials, and working with universities and companies that are assessing and developing new drug treatments. We do this to help ensure eczema research has the greatest chance of success in finding new trealments and ultimately a cure. Projects supported during the year Include.. A-STAR- UK-Irish Atopic Eczema Systemic Therapy Register BEACON Trial - Best syslemlc treatments for adults wlth atopic eczema over the long term BEACONomics- study embedded within the BEACON Trial BIOMAP InnovatNe Medicines Initiattve - Biomarkers in Atopic Dermatilis and Psoriasis END-ITCH Study - Eczema and Dermatitis, Implementing the Combined Approach Kids in Control Study- scratching awareness and behavlour change in children LEAD Study - pre-natal, pregnancy and post-natal eczema car8 and concerns of women of child bearing age Navigating Primary Care wlth Toplcal Steroid Withdrawal Study RAPID- Eczema Trials Programme SOCX Survey - looking at how skin colour affects the èxperience of people with eczema, acne and psoriasis SLEEP Study- Supportlng children's sleep in those with eczema programme SMEDISS Study- exploring social media conversations about Janus-Kinase (JAK) Inhibitor medicines TLA4AE Study- temperature controlled laminar air flow device study TRANS-FOODS Study- aiming to prevent peanut allergy. Natlonal Eczema Society provides a patient perspective for Clinical guideline development, the assessment of new eczema treatments, and policy consultations. During the year, we continued to contribute palient insights and evidence for the assessment by the National Institute of Health and Care Excellence (NICE) of a new monoclonal antit)ody drug called lebrikizumab, used to treat moderate-towsevere eczema. This was approved by NICE in June 2024 and is th8 third biologic treatment for eczema after dupilumab and tralokinumab. As eczema affects people in drfferent ways. it is very important we have a range of NHS treatment options to help ensure people can access a medicine that works effectively for them. We also provided patient evidence for the assessment by NICE of a new JAK Inhibitor topical treatment called delgocitinib for chronic hand eczema. The decision by NICE on whether delgocitinib will be approved for use by the NHS in England and Wales is expected mKI-2025. Page S
Do¢usi9n Envelopo ID: 72C948684C3F4A13-A6EB489E5E8F82CA NATIONAL ECZEMA SOCIETY (A Company Llmlted by Guarantee) Advocacy and Improving Eczema Care The charity undertakes a range of activities to raise awareness and understanding of eczema among the general public, influence for improved care, and to promote the infomiation and advice the Society provides for people living with eczema and their families. National Eczema Society scored a big win for the UK eczema community during the year. We were delighted when the MHRA, the UK medicines regulator, announced it was going to introduce clear strength labelling of topical steroids (TCS). This was in response to the Society's campaign launched a year earlier, calling on the MHRA to mandate clear strength labelling on toplcal steroid tubes. packaging and patient Informalion leaflets. Prior to thls, steroid creams and ointments used In the UK did not clearly show thelr strength on the tube or box. Topical steroids are used by millions of adults and children in the UK to treat or prevent eczema flare-ups. 11 is important patients and their carers have the right information to use these medicines safely and effectively to manage eczema well. Topical steroids are effective treatments for eczema but, like many treatments. they can have side effects. People with eczema and carers are understandably concemed about overusing TCS. We believe clear potency labelling will help improve patient understanding and confidence In these WelY-USed medicines, Our campalgn had strong support from the eczema community. Some 95Yo of respondents In our online patient survey said they wanted to see clear strength labelling on all slefoid creams and ointments. In a second patient suNey we conducted, 98Y• of respondents knew steroid creams and ointments came in different slrengths (potencies). However, almost half said they didn't know how many differenl strengths there were, and only 17% correctly answered '4.. Worryingly, 1 in 5 respondents In the survey underestimated the strenglh of their topical steroid and almosl a quarter overestlmaled this. We recommended the MHR4 use the words 'rnlld steroid,. 'moderate steroid,, 'strong steroid, or 'very strong steroid, on the labels. and we are delighted this has been adopted. The MHRA announced the change in May 2024 and gav8 manufacturers 12 months to implement the new strength labelling, which is to appear on the packaging, tube and patient information leaflet for all topical steroid products. We are grateful to the eczema community for getting behind this initiative and to the professional dennatology bodies and other charities for supporting the campaign. We believe this is a significant slep forward in supporting people to use these widely prescribed medicines safely and effectively. Representlng Patlent Vlews As a national patlenl organisalion for the UK eczema community. the Society provldes a collective volce to champion the needs of those affected by the condition, We seek to improve health outcomes for people wilh eczema by influencing health policy and participating in groups like the Dermatology Council for England and working with professional bodies like the British Assoclation of Dermatologists {BAD), British Dermatological Nursing Group (BDNG). and Primary Care Demiatology Society (PCDS). Patient interest and awareness of the side effects of topical steroid medication remains high, including concerns about topical steroid withdrawal (TSW), which feature widely on social media. Our website information on TSW is especially popular, attracting over 100,000 page views a year. TSW is complex and symptoms can be extremely painful and distressing. We are calling for more research into the causes. symptoms and treatments of TSW. National Eczema Society worked wth the British Association of Dermatologists and British Dermatological Nursing Group, to update our Joint Statement on TSW. first published 2021. We believe it is important for professional dermatological organisations and patient groups to work together to find better ways of diagnosing and supporting people with TSW. The updated Joint statement was published In February 2024. This builds on the earlier version. setting out what we know about TSW from the latest medical information available. Page 6
Drsign Envelope ID: 72C948684C3F4A1>A6EB489ESE8F82CA NATIONAL ECZEMA SOCIETY (A Company Limited by Guarantee The British Association of Demiatologists has formed a Topical Steroid Withdrawal Working Party Group. in collaboration with National Eczema Society and other organisations, with the aim of producing expert consensus guidance on to support people with concerns about TSW. This includes producing a Pats'ent Infom)ats'on Leaflet and any revisions lo the TSW Joint Statement. The work is ongoing. The UK medicines regulator, the MHRA updated Its guidance on toplcal sterold safety during the year and National Eczema Society was pleased to contribute to this review. National Eczema Society is working with corporate partner Aspire Pharma on a joint campaign to raise awareness and highlight the impact of menopause on eczema. There is limited research on the impact on women's skin during menopause. To learn more, we asked women living in the UK who are perimenopausal. menopausal or have been through the menopause to share their experiences in an online survey. We plan to announce the survey results next year. During National Eczema Week in September, we highlighted the impact of eczema on people's mental health and emotional well-being, under the theme #LetsStartTheConversation. Our campaign encouraged open dialogue about eczema with friends, family, colleagues and healthcare professionals, and we created conversallonal resources to help our community to break the silence and open up about how eczema makes you feel. People often face particular challenges managlng eczema at work, and we promoted our information resources lo support with this. Many Ihanks to everyone In our community who shared their stori&s with us, raising awareness about living with èczema and how it affects mental health. Medla and Soclal Media Engagement The Society provided information for a number of eczema stories in the media over the year. This included medla comment for stories about eczema treatments on BBC 8reakfast, synthetic skin research by Reuters. miracle eczema cures in The Telegraph, psychodermatology in the Sunday Times. and the new treatment for moderate-to-severe eczema called lebrlklzumab In a range of medla outlets. We contributed to a powerful story by the 88C in November about the huge impact eczema can have on people's lives, vAilch featured the experlences of Chlo8 North, who has also been featured In the Society's Exchange magazlne. Th8 charity was featured in several professlonal publications including Pharmaceutical Joumal. covering the MHRA announcement about new strenglh labelling for topical steroids. The So¢i8ty was approached several times for media comment about topical steroid withdrawal (TSW) and we were mentioned in a feature on this by ITV This Moming. and in a BBC online story about TSW that included comment by National Eczema Society Trustee Professor Celia Moss. We continued to expand our social media reach and activity during the year, reflecting how people increasingly seek and share information about eczema. The Society continues to grow its followers on Facebook, Instagram, Krywitter and Linkedln, with a combined social media following of over 45,000. Growlng Ineome and Bulldlng Financlal Suslalnability We continue to commit resources to income generation. to achieve our charitable objectives and build future financial sustainability. We would like to thank the many people who. as in previous years, by joining or renewing their membership. supporting our appeals and fundraising in a variety of often innovative ways, have enabled us lo continue our work. The efforts and contribution of supporters and volunteers is invaluable to the Society. In particular. we are immensely grateful to our thoughtful and generous supporters who choose to leave a gift to National Eczema Society in their Will. We are grateful also to the charitable twsts and companies that have supported us during the year, and to all the healthcare professionals who have provided us with so much time, advice and support especially members of the Medical Advisory Board. Page 7
DU51gfi Envelop9 ID.. 72C94B684C3F4A13-A6EB-889ESE8F82CA NATIONAL ECZEMA SOCIETY {A Company Limited by Guarantee) We contlnue to develop partnerships with companles that share our values and are willing to support our work and engage in joint education and awareness-raising activity. Ouring the year we worked with Abbvie. Almirall. A5plre Pharma, Biodemia, Dennal Laboratories, Lilly. LEO Pharma and Sanofi. There were many fundraising highlights during the year. Income from challenge events. including the London Marathon and Great North Run, was strong again in 2024 and we thank all our supporters for raising funds and awareness of eczema by participating in events like these. The Great South Run 2024 was cancelled at late notice due to bad weather, and we appreciated the support of our runners in this event and the funds they raised for the charity despile the disappointmenl of the event cancellation. The Soclety's West Surrey and North-East Hampshlre Support Group undertook varlous local fundralslng activities around Guildford and presented a cheque for £2.000 at the Society's Annual General Meeting in September. Our members and donors generously supported our summer and Christmas fundraising appeals once again and we are grateful to everyone who supported the Society in different ways with their donatrons. Organlsatlonal Development During the year, we implemented our plans for th8 Soclety's oftice move. The 18ase on the charity's current offices at 11 Murray Street, London NW1 9RE expires in March 2025. We started our phased move into shared workspace office5 at 82 Tanner Street, London, SE1 3GN, Unlted Kingdom in December, to be completed by end February 2025. 2025 Plans and Dovelopment Priorfties Looking ahead, we aim to ensure National Eczema Society continues to achieve the grealest impact we can for the UK eczema community including our members. The charity's core work will continue, as we expand our support for eczema r8S8arch and advocacy work in line with our strategy. We ar& celebrating th8 So¢lety'$ 50 anniversary In 2025 and will be hlghlighting thls mileston& in our charity magazine Exchange and In other communlcations. During the year wa wlll also continue scoplng work to refresh the charity's brand and visual identity. Prlorlties for 2025 include: Provldlng Informatlon and Advlce Continue providing high-quality infomiation and advice about eczema, disserninated through the Society's website, printed publications, Exchange magazine, e-newsletters. and webinars including the popular new Exploring Eczema webinar series. Scope Patienl Information Forum 'Tick' quality accreditation. Grow our social media activity and followings. including Linkedln and YouTube channel. . Supporting Eczema Research • Deliver the planned eczema and TSW research call. establishing an expert panel to assess grant applicalions and recommend resear¢h awards. • Grow our EXEC patient panel of people who are willing to share their experiences of living with eczema with researchers. Scope and provide leadership for an Eczema Priority Setting Partnership exercise in association with James Lind Alliance and other stakeholders. Consolidate our role as a 'hub' for patient and public involvement in eczema research. promoting research engagement opportunities and disseminating research findings. Page 8
DopJsi9n Envglopg ID.. 72C94B6&8C3F4A13-A6EB489E5E8F82CA NATIONAL ECZEMA SOCIETY (A Company Limited by Guarantee) Advocacy and Improvlng Eczema Care • Increase public awareness and understanding of the challenges'of living Wlth eczema. highlighting the impact on people's physical and mental health and quality of life. Lead the annual national flagship awareness event, National Eczema Week Sn September. Raise awareness of the Society's successful campaign for clearer strength labelling of topical steroids. Continue lo s¢Jpport inltiatives to promote greater understanding, diagnosis and treatment of topical steroid withdrawal. Contribute patient perspectives lo clinical guldeline development and the assessment of new treatments and policy consultations, working with regulatory bodles Including the MHRA, NICE and the SMC. Financial Results The Society planned for a modest budget surplus in 2024. following the annual £19.698 operating surplus achieved in 2023. Incom8 for the year was £529,182, with expendilure at £512.724. generatlng an annual surplus of £6.922. At 31 December 2024, the Society had reserves of £677,689 (2023.. £670,767). R•s•rve8 Polley The trustees aim to maintain adequate reserves to permit the ongoing operations of the charity. In arriving at their assessment of a suitable limit, trustees have considered the predictability of the Society's income and the nature of its expenditure, together V*Yth the degree to which these are committed. Legacies form an important part of the Society's income. and whilst legacies can often be substantial relative to overall income. they are unpredictable, and historical trends show there can be periods of years where this source of income Is much lower than the long-term average. Expendlture, on the other hand. 5s more conslstent and predlctabla. Trustees last reviewed the Reserves Policy in 2022, and considered that holding unrestricted reserves equal to approximately six months unrestricted charitable expenditure would be sufficient to close or merge the charity, should this ever ba necessary. Given the known volatility of legacy income. trustees subsequently delermined that a reserves target of 12 monlhs, future overheads expenditure would be more appropriate. However. additional spend on research in 2025 meant that this policy was not met at the end 012024 and the trustees will be conducting a further review of reseNes policy ahead of the next accounts. To make unrestricted reserves more transparent, funds that are not readily avallable to spénd are held in reserves designated for specific purposes. A key alm of the Society is to promote research into the causes and treatment of eczema. This being so. the trustees have designated a proportion of reserves to fund future research activity. in addition to any funds that donors have specrfically restricted for this purpose. Funds that are not readily available to spend, notably those represented by fixed assets. are held in a reserve designated for this purpose. The pension reserve shows future deficit payments 0d in relation to an historical d8fined benefit pension scheme (see note 20). The balance held in unrestricted funds at 31 December 2024 is £659,989 (2023.. £664,016). Unrestricted funds include funds lied up in tangible assets of £4,372 (2023: £12,903). the pension reserve of (£9,896) {2023: (£4.5671. and designated Research funds of £110,000 (2023.. £110,000}. The remaining general funds of £555,513 {2023.. £545,680) fall below the charity's reserves policy target of 12 months future overheads expenditure, budgeted at £752,600 for the 2025 financial year. Page 9
Do¢usign Envelope ID.. 72C94B68ffjC3F4A13-A6EB489ESE8F82CA NATIONAL ECZEMA SOCIETY (A Company Limited by Guarantee) Rlsk Management The trustees have tsken steps to identify and address major risks facing the Society. including maintaining a risk register. The principal uncertainty in respect lo the Socievs future is the ability to maintain sufficient incom8 to deliver the ¢haritVs operations. and ensure the Society has adequate resources to comply with regulatory changes affecting the voluntary sector. Greater focus and investment are being directed to fundraising a¢tivities, to ensure the Society generates sufficient income each year to fund planned activities. This includes building sustainable sources of non-legacy income. The principal risk of financial sustainability for the charity is closely monitored by the trustees on a regular basls, including reviewing management accounls al quarterly Board meetings. Attention also continues to focus on non-financial risks including r6PUtalion, health and safety, security, confidentiality and data protection, which are supported by appropriate policies and procedures as well as management updates as needed. The Trustees and Organisallon The Society is a charitable company. Although called trustees, we are the direclors of the company for Ihe purposes of company law. The trustees who served durin9 the year and up to the date of this report are given on page 1. The Society's governance processes are set out in Its Articles of Assoclation. The Board of Trustees administers the Society, which meets routinely four times a year and additionally as circumstances demand. A chief executive is appointed by the trustees to manag8 the day-tTrday operatlons of the Society within framework agreed by the B There must be a minimum of three trustees bul there is no maximum number, and trustees must be elected by the members of the Society at its Annual General Meeting (AGM). Trustees may be co-opted onlo the Board during the year and must then stand for election by the members at the next AGM. Al least a third of trustees are required to retire from office each year but may, if they wish, offer themselves for re-electlon at the next AGM. Trustees are recruited through the Socievs membership. local support groups. other eczema community networks and open advertising. In seeking trustees, the Soclety has re9ard of the need to ensure that the Trustee Board has an appropriat8 range of professional skills and experience, reflects our commitment to diversily, and are trustees are drawn from different areas of the UK. Although not constitutionally binding. the Society wishes to work towards aligning with the Charity Governance Code, which recommends trustees serve fixed terms in office. The guidance recommends trustees seThe an initial three-year term, with the possibility of being re-elected by members for a further three-year period. Trustees In particular roles (8.g. Chair, Treasurer) could seNe a longer nlne-year period. subject lo formal review. One current trustee has served longer than nine years and provides specific professional skills to thè Board. As yet, it has not been possible to find a replacement with comparable expertise. New trustees are provided with an introduction pack, which includes the Society's goveming documents, copies of the pasl yearfs accounts. and a briefing on their duties and responsibilities and of ihe Societys govemance processes. Prior lo joining the Board, new trustees will usually attend al least one Board meeting in an observer capacity. which gives them the opportunity to meet the trustees and chief executive. Trustees receive no remuneration and no trustee has a beneficial interest in any of the group companies. The Society has a Medical Advisory Board {MAB>, comprised of healthcare professionals who act in an advisory and ambassadorial capacity for the charity. Members volunteer their time and are all experienced healthcare professionals who work in the field of dermatology, and who have a particular professional interest in eczema management and research. The MAB is chaired by National Eczema Sociely trustee, Professor Celia Moss. Page 10
Docusign Envelope ID.. 72C94B684C3F4A13-A6EB489E5E8F82CA NATIONAL ECZEMA SOCIETY IA Company Llmited by Guarante•> The trustees set the remuneratlon of the chief executive and approve the remuneration of other Society staff, Remuneration levels are based on research of similar roles in the sector and benchmark salary data. The Trustees Report has been prepared in accordance with the provisions applicable to entities subject to the small Companies regime. Approved by order of the members of the l)oard of Truslees and signed on their behalf by: Stephen Pugh Chair September 23, 2025 Page11
Docusign Envelope10.' 72C94868*C3F4A1>A6EB489ESE8F82CA NATIONAL ECZEMA SOCIETY (A Company Limited by Guarantee) STATEMENT OF TRUSTEES. RESPONSIBILITIES FOR THE YEAR ENDED 31 DECEMBER 2024 The Trustees (who are also the directors of the Charily for the purposes of company law) are responsible for preparing the Trustees. Report and the financial statements in accordance with applicable law and United Klngdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice). Company law requires the Trustees to prepare financlal statements for each financial Under company law, th8 Trustees must not approve th8 financial stalemenls unless they are satisfied Ihat they give a true and fair view of the state of affairs of the Group and the Charity and of their incoming resources and application of resources, including their Income and expenditure, for that period. In preparing these financial statements, the Trustees are required to: select suitable arxounting policies and then apply them consistently; observe the methods and principles of the Charities SORP (FRS 102). make judgements and accounting estimates that are reasonable and prudent: state whether applicable UK Accounting Standards (FRS 102) have been followed, subject to any material departures disclosed and explained in the financial statements; prepare the financlal statements on the going concem basls unless It is Inapproprlate to presume Ihat the Group will continue in business, The Trustees are responsible for keeplng adequate accounting records that are sufficient to show and explain the Group and the Charitvs transactions and disclos8 With reasonable accuracy at any time the financial position of the Group and the Charity and enable them to ensure that th8 financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the Group and the Charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities. Approved by order of the members of the Board of Trustees and slgned on its behaff by: Stephen Pugh Chair Date.. September 23. 2025 Page 12
Owjsign Envelope 10: 72C9486&6C3F4A1>A6EB489E5E8F82CA NATIONAL ECZEMA SOCIETY (A Company Llmited by Guarantee) INDEPENDENT EXAMINER'S REPORT FOR THE YEAR ENDED 31 DECEMBER 2024 Independent Examlnerfs Report to the Trustees of Natlonal Eczema Soclety I'the Group, I report to the Charty Trustees on my examination of the consolidated accounts of the Group, set out on pages 14 lo 45, comprising the National Eczema Society {'the parent Charity) and its subsidiary undertakings for the year ended 31 December 2024. Responslbilities and Basls of Report As the Trust8es of the parent Charity (and its directors for the purposes of company law) you are responsible for the preparation of the consolidated accounts of the Group in accordance with the requirements of the Companles Act 2006 {'the 2006 Act,). Having satlsfied myself that the consolidated accounts are not required to be audited under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of the Group's accounts as carried out under section 145 of the Charities Acl 2011 ('the 2011 Act,). In Carrying out my examination I have followed the Directions given by the Charity Commission under section 145{5Xb) of the 2011 Act. Independent Examlnerfs Statement Since the Group's gross Income exceeded £250,000 your examlner must be a member of a body listed in section 145 of the 2011 Act. I confirm that l am qualified to undertake the examination because l am a member of the Institute of Chartered Accountants in England and Wales, whlch Is one of the listed bodles. I have completed my examination. l confirm that no matters have come to my attention In connection with the examination giving me cause to believe in any material respect: accounting records were not kept in respect of the parent Charity and its subsidiaries as required by section 386 of the 2006 Act: or the accounts do not accord with those records: or the accounts do not comply with the accounting requirements of section 396 of the 2006 Act other than any requirement that the accounts give a 'true and fair, view which is not 8 matter considered as part of an independent examination,, or the accounts have not been prepared in accordance wllh the methods and principles of the Statement of Recommended Practice for accounting and reporting by charities applicable to charities preparing their accounts in accordance wlth the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102). Page 13
Docusign Envelope ID: 72C9486MC3F4A1&A6EB489E5E8F82CA NATIONAL ECZEMA SOCIETY (A Company Limited by Guarantee) INDEPENDENT EXAMINER'S REPORT (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2024 I have no concerns and have come across no other matters in Connection with the examination to which attention should be drawn In thi5 report in order to enable a proper understanding of the accounts to be reached. Signed: Dated: 23 September 2025 Rachel Doyle ACA DChA MHA Chartered Accountants MHA House Charter Court Swansea Enterprise Park Swansea SA7 9FS MHA is the trading name of MHA Audit Servlces LLP, a limited liability Partnership in England and Wales (registered number OC455542}. Page 14
Docusign Envelope ID.. 72C94B6MC3F4A1>A6EB-889ESE8F82CA NATIONAL ECZEMA SOCIETY (A Company Llmited by Guarante•) CONSOLIDATED STATEMENT OF FINANCIAL ACTIVITIES (INCORPORATING INCOME AND EXPENDITURE ACCOUNT) FOR THE YEAR ENDED 31 DECEMBER 2024 Unrestricted funds 2024 Restricted funds 2024 Total fund8 2024 Total funds 2023 Note Income from: Donations and legacies Other trading activities: Income from fundraising Income from trading activities Investments 512,330 512.330 481.158 91 2,462 14,299 91 2,462 14,299 5,732 2,965 7.397 Total Income 529,182 529,182 497.252 Expendlture on: Raising funds Charitable activities 101,913 410,811 101,913 410,811 71,317 406,245 Total expendlture 512,724 512.724 477,562 Net Income Transfers beeen funds 16,458 {10,949) 16,458 19,690 21 10.949 Net movement In funds before othor recognised gains 5,509 10,949 16,458 19.690 Other recognlsed gainsl(losses): Gainsl{losses) on pension scheme (9,536) (9.536) Net movement In funds (4.027) 10,949 6,922 19.698 Reconciliatlon of funds: Tolal funds brought forward Net movement in funds 664,016 (4.027) 6,751 10,949 670,767 6,922 651,069 19.698 Total funds carrled forward 659,989 17,700 677,689 670,767 The Consolidated Statement of Financial Adivities includes all gains and losses recognised in the year. All income and expenditure derive from continuing activities. The notes on pages 21 to 45 form part of these financial ststements. Page 15
Docusign Envelope 10: 72C94B684C3F4A1&A6E8489E5E8F82CA NATIONAL ECZEMA SOCIETY (A Company Limited by Guarantee) REGISTERED NUMBER: 02685083 CONSOLIDATED BALANCE SHEET AS AT 31 DECEMBER 2024 2024 2024 2023 2023 Note Fixed assets Intangible assets Tangible ass8ts 14 15 2,255 2,117 1.462 10.733 4,372 12,195 Current ass•ts Oeblors: Amounts falling due within one year Investments Cash at bank and In hand 17 18 116,944 253,616 428,458 88.906 728,799 799,018 817,705 Current Ilabllities Creditors.. Amounts falling due within one year 19 (118.7501 (158,773) Net current assets 680,268 658.932 Total assets less current Ilabllltles 684,640 671.127 Creditors.. Amounts falling due after more than one year 20 {6,951> (360) Total net ass•ts 677,689 670,767 Group funds Restricted funds Unrestricted funds 21 21 17.700 659,989 6,751 664,016 Total funds 677,689 670,767 Page 16
Do¢usiw Envelope ID.. 72c94B6c3F4A13-A6E889EsE8F82CA NATIONAL ECZEMA SOCIETY (A Company Limited by Guarantee) REGISTERED NUMBER: 02685083 CONSOLIDATED BALANCE SHEET (CONTINUED) AS AT 31 DECEMBER 2024 The Charity was entitled to exemption from audit under section 477 of the Companies Act 2006. The members have nol required the company to obtain an audit for the year in question in accordance with section 476 of Companies Act 2006. The Trustees acknowledge their responsibilities for complying with the requirements of the Act with respect to 8ccounlin9 records and preparation of financial stalemènts. Th8 financial statements have been prepared In accordance vth the provlslons applicable to entities subject to the small companies regime. The financial statements were approved and authorised for issue by the Trustees and signed on their behalf by: stephen Pugh Chair Date.. September 23, 2025 The notes on pages 21 to 45 form part of these financial statements. Page 17
DUSi Envelope ID.. 72C94B684C3F4A1>A6EB-889E5E8F82CA NATIONAL ECZEMA SOCIETY (A Company Limited by Guarantee) REGISTERED NUMBER: 02685083 CHARITY BALANCE SHEET AS AT 31 DECEMBER 2024 2024 2024 2023 2023 Note Flxed assets Intangible assets Tangibl8 assets Investments 14 15 16 2,255 2,117 100 1,462 10.733 100 4,472 12.295 Current assets Oebtors: Amounts falling due within one year Investments Cash at bank and in hand 17 18 116,944 253,616 336,093 154.841 581,497 706.653 736,338 Current liabSlltle$ Creditor5: Amounts falling due within one year 19 (124,480) (115,791) N•1 ¢urrent assèts 582,173 620.547 Total assets less current Ilabllltles 586.645 632.842 Creditors: Amounts falling due after morè than one year 20 (6,951) (360) Total net assets 579,694 632,482 Charlty funds Restricted funds Unrestricted funds 21 6,751 625,731 21 579,694 Total funds 579,694 632,482 Page 18
Docusign Envelope ID: 72C94B6MC3F4A1>A6EU89E5E8F82CA NATIONAL ECZEMA SOCIETY IA Company Llmlted by Guarantee) REGISTERED NUMBER: 02685083 CHARITY BALANCE SHEET (CONTINUED) AS AT 31 DECEMBER 2024 The Charitys net movement in funds for the year was £(52.788) (2023 - £(48.111 )). The Charity was entitled to exemption from audit under section 477 of the Companies Act 2006. The members have not requlred the company to obtain an audit for the year in questlon in accordance with section 476 of Companies Act 2006. The Trustees acknowledge their responsibilities for complylng with the requlr8ments of the Act with respect to accounting records and preparation of financial statements. The financial statements have been prepared in accordance with the provlslons applicable to entities subject to the small companies regime. The financial statements were approved and authorised for issue by the Trustees and signed on their behalf by: Stephen Pugh Chair Date.. September 23, 2025 The not88 on pages 21 to 45 form part of these financlal slatem8nts. Page 19
Oocusign Envelope ID.. 72C94668-6C3F4A13-A6EB-889E5E8F82CA NATIONAL ECZEMA SOCIETY (A Company Llmited by Guarantee) CONSOLIDATED STATEMENT OF CASH FLOWS FOR THE YEAR ENDED 31 DECEMBER 2024 2024 2023 Note Cash flows from operallng actlvltles Net cash used in operatlng activities 22 (308,540) 38.315 Cash flows from Investing activities Investment income 14,299 (2,000) (4.100) 7.397 {2.021) (2,000> Purchase of intangibl8 assets Purchase of tangible fixed assets Net cash provid•d by Investlng activities 8,199 3,376 Change In cash and ea8h equlvalents In the year Cash and cash equivalents al the beginnlng of the year (300,341) 728,799 41,691 687,108 Cash and cash equlvalenls at the end of the year 23 428,458 728.799 The notes on pages 21 to 45 form part of these financial statements Page 20
Do¢usign Envelope ID.. 72C94B684C3F4A1&A6E&889E5E8F82CA NATIONAL ECZEMA SOCIETY (A Company Limlted by Guarantee) NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2024 Gen6ral Informatlon Natlonal Eczema Society is a charitable company limlted by guarantee and is reglstered with the Registrar of Companies (Company Registered Number: 02685083), the Charity Commission in England and Wales {Charily Registered Number: 1009671). In the event of the Charity being wound up. the liability in respect of the guarantee is limited to £1 per Member of the Charity. The address of the regislered office is given in ihe Charity information an page 1 of these financial slatem8nts. The nature of the Charitys operations and principal activities are detailed in the Trustees, Report. The significant accounting pollcies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all years presented unless otherwise stated. Accounting policies 2,1 Basls of preparatlon of flnanclal statements The financial statements have been prepared in accordance with the Charities SORP {FRS 102) Accounting and Reporting by Charities: Statement of Recommended Practice applicable lo charilies preparing their accounts in accordance with the Financlal Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Companies Act 2006. National Eczema Society meets the definition of a public benefit ents'ty under FRS 102. Ass8ts and liabilities are initially recognised at historical cost or transaction value unless OtheIse stated in the relevant accounting policy. The Consolidated Statement of Financlal Actlvities (SOFA) and Consolidaled Balance Sheet consolidate the financlal statements of the Charity and its subsldiary undertaking. The results of the subsidiary are consolidated on a line by line basis. The financial statements are prepared in sterling which is the functional and presentstional currency of the Group and are rounded to the nearest pound. 2.2 Going ¢oncem The Trustees have assessed the use of going concern and have conSided possible events or conditions that might cast signficant doubt on the ability of the Group to conlinue as a going concem. The Trustees have made this assessment for a period of at least one year from the date of the approval of these financlal statements. The Trustees have concluded that there 18 a reasonable expectation that the Group has adequate resources to continue in operational existence for the foreseeable future, and that no malerial uncertainties exist. The Group therefore continues to adopt the going concern basis in preparing these financial statements. Page 21
DorAJsign Envelope ID.. 72C94B684C3F4A1&A6EB-889E5E8F82CA NATIONAL ECZEMA SOCIETY (A Company Llmited by Guarantee) NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2024 Accounting pollcles (continued) 2.3 Income All income is recognised On the Group has entitlement to the income, it is probable that the income will be rettived and the amount of income CeIVable can be measured reliably. For donations and gift aid to be recognised the Group will have been rtified of the amounts and the settlement date in writing. If there are conditions attached to the donation and this requires a level of performance before entitlement can be obtained then income is deferred until Ihose conditions are fully met or the fulfilment ol those conditions is within the control of the Group and il is probable that they will ba fulfilled. The recognition of income from legacies is dependent on establishing entitlement, the probability of receipt and the ability to estimate with sufficient accuracy the amount receivable. Evidence of entitlement to a legacy exists when the Group has sufficient evidence that a gift has been left to them (through knowledge of the existence of a valid will and the death of the benefactor) and Ihe executor is satisfied that the property in question will not be required to satisfy claims in the estate. Receipt of a legacy must be recognised when tt is probable that it will be received and the fair value of the amount receivable, which will generally be the expected cash amount to be distributed to the Group, can be reliably measured. Subscription income is received in full and recogni88d evenly over the course of the subscription. The amount recognised In the Consolidated Statement of Financial Activities relales to the financial period in question. Income from trading activities includes income earned from fundraising events and trading activities to raise funds for the Group. Income is received in exchange for supplying goods and services in order to raise funds and is recognised when entitlement has occurred. Corporate membership income is received in full and recognised evenly over the course of the membership. The amount recognised in the Consolidatèd Statement of Financial Activities relates to the financial perlod in question. 2.4 Expenditure All expenditure is accounted for on an accruals basis and has been classified under headings that aggregate all costs relaled to the categories. Expenditure is recognised once there is a legal or constructive obligation lo transfer economic benefit to a third party. it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can b8 measured reliably. Expenditure is classified by activity. The costs of each activity are made up of the total of direct costs and shared costs, including support costs involved in undertaking each activity. Direct costs attributable lo a single activity are allocated directly to Ihat activity. Shared costs which contribute to more than one activity and support costs which are not attributable to a single aciivity are apportioned between those activities on a basis consislent with the use of resources. Central staff costs are allocated on Ihe basis of time spent, and depreciation charges allocated on the portion of the assel's use. Expenditure on charitable activities is incurred on directly undertaking the activities which further the Group's objectives, as well as any associated support costs. All expenditure is inclusive of irrecoverable VAT. Page 22
Docusign Envelope ID.. 72C948684C3F4A1>A6E8-889E5E8F82CA NATIONAL ECZEMA SOCIETY (A Company Llmlted by Guarantee) NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2024 Accounllng policies (contlnued) 2.5 Interest recelvable Interest on funds held on deposit is included when receivable and the amount can be measured reliably by the Group: this is nomially upon notification of the interest pald or payable by the inslitution with whom the funds are deposited. 2.6 Taxation The Charity is considered to pass the tests set out in Paragraph 1 Schedule 6 of the Finance Act 2010 and therefore It meets the definition of a charitable company for UK corporation tax purposes. Accordingly, the Charity is potentially exempt from taxation in resp8Ct of income or capital gains received within categories covered by Chapter 3 Part 11 of the Corporats'on Tax Act 2010 or Section 256 of the Taxation of Chargeable Gains Act 1992. to the extent that such income or gains are applied exclusively to charitable purposes. 2,7 Intanglble assets and amortlsatlon Intangible assets costing £500 or more are capilalised and recognlsed when future economic benefits are probable and the cost or value of the asset can be measured rellably. Intangible assets are initially recognised at Gost. After recognition, under the cost model. intangible assets are measured at cost less any accumulated amortisats'on and any accumulated impairment losses. Amortlsalion Is provided on Intangible assets at rates [CUlated to wrlte off the cost of each asset on a straight4ine basis over 3 years. Assets under construction a not amortised until ready for use. 2.8 Tanglble fixed assets and depreciation Tangible fixed assels costing £500 or more are Capitalised and recognised when future economic benefils are probable and the cost or value of the asset can be measured reliably. Tangible fixed assets ar8 initially recognlsed at cost. After recognitlon. und8r lh6 cost model. tangible fixed assets are measured at cost less accumulated depreciation and any accumulated impairment losses. All costs incurred to bring a tangible fixed asset into its Intended working condition should be induded in the measurement of cost. At each reporting date the Group assesses whether there is any indication of impairment. If such indication exists, the recoverable amount of the asset is determined to be the higher of its fair value less costs to sell and its value in use. An impaimient loss is recognised where the carrying amount exceeds the recoverable amount. Page 23
Docusign Envelope ID.. 72C94B6c3F4Al3-A6EB-889EsE8F82CA NATIONAL ECZEMA SOCIETY (A Company Llmited by Guarantee) NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2024 Accounting policles (continued) 2.8 Tanglble fixed assets and depreciation {contlnued) Depreciation is charged so as to allocate the cost of tangible fixed assets less their residual value over their estimated useful lives, using the straight-line method. Depreciation is provlded on the following bases.. Leasehold Improvements Furniture and fittin9S Office equipment Computer equlpment over 10 years over 10 years over 10 years over 3 years 2.9 Investments The investment In the subsidiary company is valued at cost less provlslon for impairment. 2.10 Debtors Trade and other debtors are recognised at the settlement amount after any trade discount offered. PrepayTnents are valued at the amount prepaid net of any trade discounts due. 2.11 Cash at bank and In hand Cash al bank and in hand Indudes cash and short-temi hlghly liquid investments with a short maturily of three months or less from the date of acquisition or opening of the deposit or slmilar account. 2.12 Llabilities and provlslons Liabilities are recognised when there is an obligation at the Balance Sheet date as a resull of a past event, It is probable that a transfer of economic benefit will be required in settlement. and the amount of the settlement can be estimated reliably. Liabilities are recognised at the amount that the Group anticipates It wlll pay to settle the debt or the amount it has received as advanced payments for the good5 or services it must provide. Provisions are measured at the best estimate of th8 amounts required to settle the obligation. Where the effect of the time value of money is material, the provision is based on the present value of those amounts. discounted at the pre-tax discount rate that reflects the risks specific to the liability. The unwinding of the discount is recognised in the Consolidated Statement of Financial Activities as a finance cost. Page 24
Docu$*J Envelope ID.. 72C94B684c3F4Al&A6E89ESE8F82CA NATIONAL ECZEMA SOCIETY (A Company Llmlted by Guarantee) NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2024 Accounting poll¢les (continued) 2.13 Flnanclal Instruments The Group only holds basic Financial Instruments. The financial assets and financial liabilities of the Group are as follt)WS: Debtors other debtors are baslc finanGlal instruments and are debl Snstruments measured at amortised cost as detailed in Note 17. Cash at bank- is classified as a basic financial instrument and is measured at face value. Llabilities accruals are classlfied as financlal Instruments. and are measured at amortised cost as detailed in Notes 19 and 20. 2.14 Operatlng leases Rentals paid under operating leases are charged to the Consolidated Statement of Financial Actlvltles on a straight line basls over the lease tem). 2.15 Penslons Through its past participation, the Group has a liability to a pension scheme called the S8ri8s 3 Growth Plan. which closed in 2013. Slnce then, the Group has particlpaled in a defined contributs'on pension scheme for employees, operated by workplace pension provider TPT. The Group Is part of the Series 3 Growth Plan which is a multi-employer penslon Scheme whlch closed in 2013. The Scheme administrators have confirmed that it is not possible to separately identify the assets and liabilities of participaling employers on a consistent and reasonable basis. The assets of the Scheme are Cowmingled for investment purposes and benefits are paid from total Scheme assets. A deficit reduction plan has been agreed. The Group accounts for ils participation in this Plan as a defined contribution plan, as there is insufficient infomiation available to account for this as a defined benefit plan, as the share of ils assets and liabilities cannot be identified. To avold crystallizing an immediate payment of the apparent under-funding in the Seri8s 3 Scheme, the Group Is participating in Ihe Series 3 Recovery Plan and the liabillty Is included in Noles 19 and 20. The Group recognises its liability lo make payments to fund the deficit relating to pasl service under an agreement lo make those payments. It recognises the full liability for the present value of contribulions payable that results from the agreement for funding the multi employer plan. The Group also participates in a defined contribution pension scheme for its employees. The Group pays fixed contributions into a separate scheme. Once the defined contribution payments have been made. the Group has no further payment obligations in respect of this scheme. The contributions are recognised as an expense in the Consolidated Statement of Financial Activities as they fall due. Page 25
Docuslgn Envelope 10.. 72C94B68-6C3F4A1&A6EB489E5E8F82CA NATIONAL ECZEMA SOCIETY (A Company Llmlted by Guarantee) NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2024 Accountlng pollcles {contlnued) 2.16 Fund accountlng General funds are unrestricted funds which are available for use at the discretion of the Trustees in furtherance of the general objectives of the Group and which have not been designated for other purposes. Designated lunds comprise unreslricted funds that have been set aside by the Trustees for particular purposes. The aim and use of each designated fund is set out in the notes to the financial statements. Restricted funds are funds whlch are to be used In accordance with speclfic restrictions Imposed by donors or which have been raised by the Group for particular purposes. The costs of raising and administering such funds are charged against the speclfic fund. The aim and use of each restricted fund is set out In the notes lo the financial statements. Investment income, galns and losses are allocated to the appmpriate fund. Critical accounting estimates and areas of Judgement Estimates and judgements are continually evaluated and are based on historical experienc8 and other factors, including expectations of future events that are believed to be reasonable under the circumstances. Critical accounting estimates and assumptions: The Group makes estimates and assumptions concernlng the future. The resulting accounting estimates and assumptions will, by definition, seldom equal the related actual results. The estimates and assumptions that have a slgnificant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year are listed below. Allocation of support costs Legacy income recognition Depreciation rates for tangible fixed assets Useful economic lives of assets The discount rate used in valuing the year-end Pension Scheme deficit. Page 26
Docusign Envelope ID.. 72C94B6C3F4Al3.A6E89EsE8F82CA NATIONAL ECZEMA SOCIETY (A Company Limited by Guarantee) NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2024 Income from donatlons and legacles Unrestricted funds 2024 Total funds 2024 Donations and similar income Legacies Subscriptions Gift aid 175.519 189.454 126.734 20.623 175,519 189,454 126,734 20,623 Total 2024 512,330 512,330 Unrestricted funds 2023 Total funds 2023 Donations and similar income Legacies Subscriptions Gift aid 205,431 110.610 141.813 23.304 205,431 110,610 141,813 23,304 Total 2023 481,158 481,158 Page 27
Docusign Envelope ID.. 72C94B684C3F4A1>A6EU89E5E8F82CA NATIONAL ECZEMA SOCIETY (A Company Limited by Guarantee) NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 310ECEMBER 2024 Incom• from other Iradlng actlvltles Income from fundralslng events Unreslricted funds 2024 Totsl funds 2024 Other actlvltles 91 91 Unrestrict8d funds 2023 Total funds 2023 Other corporate Income Other activities 2.896 2,836 2,896 2,836 Totsl 2023 5,732 5.732 Income from non charltable tradlng actlvltles Unrestrlcted funds 2024 Total funds 2024 Trading subsidiary 2,462 2,462 Unrestricted funds 2023 Total funds 2023 Tradlng subsidiary 2,965 2,965 Page 28
Docusign Envelope ID.. 72C948684C3F4A13A6EB-889E5E8F82CA NATIONAL ECZEMA SOCIETY (A Company Limited by Guarantee) NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2024 Income from investments Unrestricted funds 2024 Total funds 2024 Bank Inte$t receivable 14.299 14,299 Unrestricted funds 2023 Total funds 2023 Bank interest receivable 7.397 7,397 Page 29
Do¢usign Envelope ID.. 72C94868*C3F4A13-A6E89EsE8F82CA NATIONAL ECZEMA SOCIETY (A Company Llmlted by Guarantee) NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2024 Expenditure on ralslng funds 2024 2023 Fundralslng Costs Oirect costs Support costs 78,339 23.572 65,707 5,604 101,911 71,311 Analysis of support costs - fundraising costs 2024 2023 Staff costs Depreciation Premlses costs 6,368 1,212 2,451 264 149 1,377 129 3.794 6,757 1,071 1.912 382 728 Carrlage and postage HCP services and fees Professional fees Bought-in services Website, database and computing Other costs Govemance costs 116 33 349 41 712 835 496 23,572 5.604 2024 2023 Tradlng costs Trading subsidiary- Direct costs In both the current and previous financial years all Expenditure on raising funds was from Unrestricted funds. Page 30
Docusign Envelope ID.. 72C94B684C3F4A13-A6EB-889E5E8F82CA NATIONAL ECZEMA SOCIETY IA Company Llmlted by Guaranto01 NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2024 Analysls of expenditure on charitable activities - by fund Unre$trl¢ted funds 2024 Total 2024 Communlcations. awareness and campaigns Health Information and Advice Research 88,371 219,290 103.150 88.371 219.290 103,150 Total 2024 410.811 410.811 Unrestricted funds 2023 Tot81 2023 Helpline Membership services Infomiation services 110,547 181,415 114,283 110,547 181,415 114,283 Totsl 2023 406.245 406.245 Page 31
Docusign Envelope ID: 72C94B684C3F4A13.A6E8-889E5E8F82CA NATIONAL ECZEMA SOCIETY (A Company Limited by Guarantee) NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2024 Anatysis of expenditure on charltable activltles - by type Activltles undertaken directly 2024 Support costs 2024 Total funds 2024 Communicalions, awareness and campaigns Health Inlormalion and Advice Research 12.523 101.432 79,577 75.848 117.858 23,573 88,371 219,290 103,150 Total 2024 193,532 217,279 410,811 Activities undertaken directly 2023 Support costs 2023 Total funds 2023 Helpline Membership servlces Infom)atlon services 60,804 102,860 73.335 49.743 78.555 40.948 110.547 181.415 114.283 Total 2023 236,999 169,246 406,245 During the year the charity restwctured its activities and therefore the prior year is not directly comparable to the current year. If the current year was allocaled on the same basis as previous years the total expenditure for each activity would be as follows= Raising Funds £86.710 Helpline £108,713 Membership services £201.896 Information services £106,405 Page 32
DrKu%gn Envelope10: 72C94BC3F4Al3-A6EB4B9ESE8F82CA NATIONAL ECZEMA SOCIETY (A Company Llmited by Guarantee) NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2024 Analysis of expendlture on charitable actlvStles - by type (contlnued) Analysls of support costs Total funds 2024 Total funds 2023 Staff costs Depreciation Premises costs Carrlage and postsge Professlonal fees 8ought-in seryices Website, database and computing Insurance Other costs Governance costs 57,314 10,910 22,064 2.373 12,390 1,161 34,149 231 65,711 9.636 1.340 55.947 11.165 21,302 3.399 13.130 1,205 20,833 1,750 27,930 11.619 966 HCP services and fees 217,279 169,246 10. Governance costs 2024 2023 Independent Examinefs remuneration Staff training Insurance Recruitment Rooiii hire & Conference expenses Truslees expenses Travel, hotels & subsistence General office expenses 2,535 2,000 2.065 5,789 7,626 202 1.498 344 639 26 10,707 12.017 Total Govemance costs above Comprise £1,071 (2023 - £398) of Expenditure on raising funds and £9,636 (2023- £11,619) of Expenditure on charitable activities. Page 33
Docusign Envelopg ID: 72C94888-6C3F4A1>A6EB-889E5E8F82CA NATIONAL ECZEMA SOCIETY (A Company Limlted by Guarantee) NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2024 11. Audltors. and Independent oxamlner's ramunoratlon 2024 2023 Independent Examinerfs remuneration - Examination of the financial statements 5.520 5,250 12. Staff costs Group 2024 Group 2023 Charlty 2024 Charity 2023 Wages and salaries Social security costs Pension costs 238,434 23,212 7,849 212,525 19,710 10,327 238,434 23,212 7,849 212,525 19.710 10.327 269,495 242,562 269,495 242.562 Included In Wages and salarles above a redundancy costs of £29,812 (2023., £NIL). Of thls amount. £29.812 (2023: £NIL) relates to statutory redundancy. The average number of persons employed by the Charity during the year was as follows: Group 2024 No. Group 2023 No. Direct charltable activities Fundraising and communication Support and governance The number of employees whose employee benefits (excluding employer pension costs) exceeded £60,000 was: Group 2024 No. Group 2023 No. In the band £60,001- £70,000 In the band £70.001- £80,000 The total amount of employee benefits. including employers national insurance and pension contributions, received by Key Management Personnel is £102.576 (2023 - £138,823). The Charity considers its Key Managemenl Personnel comprise the Trustees and the Chief Executive Officer and deputy CEO. Page 34
Docuslgn Envelope ID.. 72C94B684C3F4A1&A6E&889E5E8F82CA NATIONAL ECZEMA SOCIETY (A Company Limlted by Guarantee) NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2024 13. Trusle•s' remuneratlon and expenses Durlng the year, no Trustees received any remuneration or other benefits (2023 - £NIL). During the year ended 31 December 2024. expenses totalling £147 were reimbursed or paid direclly to 1 trustee (2023 - £499 - 2 Trustees) in relation to travel and conference costs. 14. Intangible assets Group and CharSty Wobslte Cost At 1 January 2024 Disposals Revaluations 23,009 120.988) 2.000 At 31 December 2024 4,021 Amortlsallon At 1 January 2024 Charge for the year On disposals 21.547 1,210 (20,9911 At 31 December 2024 1,766 Not book value At 31 December 2024 2,255 Al 31 December 2023 1.462 Page 35
DO$19n Envelope10'. 72C94B68-6C3F4A1&A6EB489E5E8F82CA NATIONAL ECZEMA SOCIETY (A Company Limlted by Guarantee) NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2024 15. Tanglble flxed assets Group and Charlty Leasehold Improvemen Furnltur8 ts and fixtures Officè equlpment Computer equlpment Total Cost or valuatlon At 1 January 2024 Additions Disposals Transfers befvéeen dasses 41,470 1,330 2,493 3,873 26,189 2,770 (22,044) (2.000) 74,025 4,100 (22,221) (2.000> 1177) At 31 December 2024 42,800 2,493 3,696 4,915 53.904 Depreclatlon At 1 January 2024 Charge for the year On disposals 34,230 8,570 2,178 315 3.063 23,821 1,288 {22,041) 63,292 10,713 122,218) (177) At 31 December 2024 42,800 2,493 3,426 3.068 51,787 Net book valu• Al 31 December 2024 270 1,847 2,117 At 31 December 2023 7,240 315 810 2,368 10,733 Page 36
Oocusiw Envelope ID.. 72c94e63F4A13-A8EB489E5E8F82CA NATIONAL ECZEMA SOCIETY (A Company Llmlted by Guarantee) NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2024 16. Fixed asset Investments Investment in subsldlary company Charlty Cost or valuation At 1 January 2024 100 At 31 December 2024 100 Prlnclp41 $ubsldlarles The following was a subsidiary undertaking of the Charity: Name Company Reglstered office or number prlnclpal place of business Holding Included In consolldation Eczema Trading Llmlted 06895048 82 Tanner Street, London, SE13GN 100% Yes The financial results of the subsidiary for the year were: Name Income Expendlture Proflt for the year Net assets Eczema Trading Llmiled 69,712 15,002) 64,710 103,095 The results of Eczema Trading Limited are included in these consolidated accounts. Eczema Trading Limited did not meet the audil Ihreshold and therefore did not require an audil for the year ended 31 December 2024. The reported surplus relates to intercompany management charges and minimal advertising and corporate membership revenue. For the year ended 31 December 2024, Corporate memberships. the advertising revenue from our membership magazine, together with limited income from company supporters, is accounted for in Eczema Trading Limlted. Page 37
DUkn Envelope ID.. 72C94B68-6C3F4AI&A6EB-889E5E8F82CA NATIONAL ECZEMA SOCIETY (A Company Llmlted by Guarantee) NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2024 17. Debtors Group 2024 Group 2023 Charity 2024 Charity 2023 Due within one year Trade debtors Amounts owed by group undertakings Other debtors Prepayments and accrued Income 20.762 2.762 83.935 50.622 17.522 94,075 22,869 50,622 17,522 94,075 22,869 116,944 88,906 116,944 154,841 18. Current as$•t Investmants Group 2024 Group 2023 Charlty 2024 Charity 2023 95 day savings accounts 253,616 253,616 Page 38
Docusign Etwglope 10.. 72C94868-6C3F4A13-A6EB489E5E8F82CA NATIONAL ECZEMA SOCIETY (A Company Llmlted by Guarantee) NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2024 19. Creditors: Amounts falling due within one year Group 2024 Group 2023 Charlty 2024 Charity 2023 Trade creditors Amounts owed to group undertakings Other tsxation and social security Other creditors Accruals and deferred income 2,881 5.127 2,881 41,462 12,326 3,998 63,813 5,127 12,326 3,998 99,545 15,401 4,395 133,850 15,401 4,395 90,868 118,750 158,773 124,480 115.791 Group 2024 Group 2023 Charity 2024 Charity 2023 Oeforred Income Deferred Sncome at 1 January Resources deferred during the year Amounts released from previous perlods 115,512 78.080 97,525 164,308 {133,616) {126,876) 72,530 15,000 (45,916) 50,447 77,409 (55.326} Defèrr•d Income at 31 Dec•mb•r 79,421 115,512 41,614 72,530 Deferred income consists of membership income relating to future periods. Page 39
Dowsign Envelope ID: 72c94B6C3F4A1M6EBB9E5E8F82CA NATIONAL ECZEMA SOCIETY (A Company Limited by Guarantee NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2024 20. Credltors: Amounts falling due after more than one year Group 2024 Group 2023 Charlty 2024 Charity 2023 Pension Scheme deficlt 6.951 360 6,951 360 Through its past participation. the Group has a liability to a pension scheme called the Series 3 Growrth Plan. which closed in 2013. Since then, the Group has participated in a defined contribution pension scheme for employees, operated by workplace pension provider TPT. The Charity is participating in a recovery plan to eliminate ils Serles 3 scheme deficit over a ten year perlod. The Pensions Trust, the scheme administrator, has however advised that the amount of employer debt on the alternative of withdrawal from the Series 3 scheme has been estimated by actuaries to have been £200,161 as at 31 December 2016. As the Charity intends to continue participating in the recovery plan, no provision has been made for this potential withdrawal debt however, the Society accounted for the present value of all remaining contributions under the recovery plan in th8 2017 accounts at their present value of £120,000, as advised by the scheme administrator. This liability has been adjusted annually to unwlnd th8 rel8vant discount applied. In order to meet thelr share of the shortfall, the Charity has been asked to pay addits'onal contrlbutlons to the scheme. A full actuarial valuation was carried out by the actuaries during the year and the funding shortfall calculated at that date gave rise to a remeasurement reduction of £9,896 in the deficit as at 31 December 2024. The deficit of the scheme is £9,896, (2023- £4.556) at 31 December 2024. The payment by the Charity in the year was £4,324 (2023 - £4,324) with an interest payment of £129 (2023 - £311) and a revaluation gain of £Nil (2023- £8). In addition. the Char5ty elected to switch, with effect from 1 October 2013, from Series 3 to Series 4. a defined contributlon scheme. The pension cost in the accounts represents amounts payable by the charity as ordinary employer contributions to the Serles 4 defrd contrlbution fund. During Ihe year employer contributions of £7,849 (2023 - £10.327), interest of £42 (2023 - £311), actuarial (gains)Ilosses of £Nil (2023 - £8) and remeasurements for amendments to the contribution schedule of £9.525 (2023 - £Nil) have been charged to the Consolidated Statement of Financial Activities. along with scheme costs of £5,091 (2023.. £3.625). There were no accrued contributions at 31 December 2024 (2023 £NIL) bul there is a liability of £9,896 (2023 - £4,566) for future contributions under the Series 3 Recovery Plan. 01 this £2,945 (2023 - £4,206) is reported in Creditors.. Amounts falling due within one year as part ol Other credltors and £6.951 (2023 - £360) is reported in Creditors.. Amounts falling due after more then one year. Page 40
Docusign Envelope ID.. 72C94B6C3F4AlmsE889E5e8F82CA NATIONAL ECZEMA SOCIETY (A Company Limlted by Guarantee) NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2024 21. Statement of funds Statement of funds - current year Balance at 31 Galnsl December (Losses) 2024 Balance at I January 2024 Transfers Inllout) Income Exp•nditur• Unrestricted funds Deslgnated funds Fixed asset fund Pension reserve Research fund 12,903 (4,567) 110,000 (10,910) (5,132) 2.379 9.339 4,372 (9,896) 110.000 (9,5361 118,336 {16,042) 11,718 (9,536) 104,476 General fund¥ General funds 545,680 S29,182 1496,682) (22,667} 555,513 Totsl Unrestrlcted funds 664,016 529,182 (512,724) (10,949) (9,536) 659,989 Restrlcted fund8 Research 6,751 10,949 17,700 Total of funds 670.767 529,182 {512,724) (9,536) 677,689 Page 41
Docuskjn Envelope10: 72C948684C3F4A13-A6EB489ESE8F82CA NATIONAL ECZEMA SOCIETY (A Company Llmlted by Guarantee) NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2024 21. Statement of funds (continued) Statement of funds - prlor year Balance at 31 Galnsl December (Losses) 2023 Balance at 1 January 2023 Transfers inlout Income Expenditure Unrestricted funds Deslgnated funds Fixed asset fund Pension reserve Research fund 19.721 (8,587) 110,000 (10.839) (5.579) 4,021 9,591 12.903 (4,567) 110,000 121,134 {16,418) 13,612 118,336 General funds General funds 523,185 497,252 {461,145) <13,612) 545.680 Total Unrestrlcted funds 644.319 497.252 (477,563) 664,016 Restricted funds Research 6.751 6,751 Total of funds 651,070 497,252 (477,563) 670,767 Page 42
DLKusign Envelope ID.. 72C94B6MC3F4A1>A6E&889E5E8F82CA NATIONAL ECZEMA SOCIETY (A Company Limited by Guarantee) NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2024 21. Statamenl of funds (contlnuedl D sl nated funds The Pension reserve has been estsblished to show the future pension deficit payments in regards to a defined benefit pension scheme. This pension scheme is being treated as a defined contribution pension scheme as a reliable estimate cannot be made of the liability at the year end. The transfer of £9,339. was made to separate the deficit paymenls due as at 310ecember 2024 from Ihe Unrestricted general fund. Actuarial gains l (losses> are charged lo this fund as they arise. The Fixed asset fund has been established to reflect the funds tled up in Tangible and Intangible fixed assets and agrees back to the Net Book Value presented on the Consolidated Balance Sheet. Depreciation is charged to this fund as expenditure. The Research fund has been established to designale funds for research into the causes and treatment of eczema, which is a key aim of the Society. The Society will provide grants to researchers on a periodic basis and it is necessary to designate sufficient reserves to fund the expected grant costs. Unrestricted funds General funds reflects funds which are available for use at the discretion of the Trustees in furtherance of the general objectives of the Charity and which have not been deslgnated for other purposes. R strlcted The Research fund exists to provlde resources for research Into the causes of eczema, wlth the aim of developing more effective treatments or a cure. 22. Reconclllallon of net movement In funds to net cash flow from operatlng actlvities Group 2024 Group 2023 Net income for the period (as per Statement of Financial Activities) 16,458 19.690 Adjustmonts for: Depreciation charges Amortisalion charges Dividends, inte$tS and rents from investments Loss on the sale of fixed assets Increase in debtors (Decrease)lincrease in creditors Actuarual Gainsl {loss} on pension 10,713 1,210 (14,299 2,000 (281,654) (33,432) (9,536) 9,1S2 2.395 {7.397) (53.516) 60,041 Net cash provided byl(used in) operating activities (308,540 30.365 Page 43
Docusign Envelope ID.. 72C94868ffjC3F4A13-A6E&889E5E8F82CA NATIONAL ECZEMA SOCIETY (A Company Llmited by Guarantee) NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2024 23. Analysls of cash and cash equlvalents Group 2024 Group 2023 Cash in hand 428,458 728.799 Total Cash and cash equlvalents 428,458 728.799 24. Analysls of changes In net debt At1 January 2024 Cash flows At31 December 2024 Cash at bank and in hand 95 day savlngs accounts 728,799 (300,341) 253,616 428,458 253,616 728,799 (46,725) 682,074 25. Operatlng lease commltments At 31 December 2024 the Group and the Charity had commitments to make luture mlnlmum lease payments under non-cancellable operating leases as follows.. Group 2024 Group 2023 Charlty 2024 Charity 2023 Not later than 1 year Later than 1 year and not laler than 5 years 30,600 21,000 4,333 30,600 21,000 4.333 30,600 25.333 30.600 25,333 The following lease payments have been recognised as an expense in the Statement of Financial Activities- Group 2024 Group 2023 Charity 2024 Charity 2023 Operating lease rentals 21.000 21.000 21,000 21.000 Page 44
Oocusign Envelope ID.. 72C948684C3F4A13-A6E8489E5E8F82CA NATIONAL ECZEMA SOCIETY (A Company Llmited by Guarantee) NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2024 26. Related party transactlons In the year ended 31 December 2024, unrestricted donations of £120 (2023 - £120) were made by the Trustees of the Chaflty. 27. Post balance shMt events The charity has received a legacy from the Morton Estale. There are a number of assets that are in the procéss of being sold and therefore the expected legacy could not be accurately valued at the year end. The charity also received a legacy from Enld Mary Shores Estate. The amount received could not be quantified at the year end. Page 45